[Objectives]The paper was to investigate the clinical effect of Fuyang prescription in the treatment of yang deficiency syndrome in the convalescent stage of ischemic stroke(IS)and its mechanism of action.[Methods]A t...[Objectives]The paper was to investigate the clinical effect of Fuyang prescription in the treatment of yang deficiency syndrome in the convalescent stage of ischemic stroke(IS)and its mechanism of action.[Methods]A total of 50 patients with yang deficiency syndrome in the convalescent stage of IS were randomly divided into treatment group and control group,with 25 patients in each group.The patients in the treatment group were given basic treatment combined with Fuyang prescription,and those in the control group were given basic treatment combined with Buyang Huanwu decoction;the course of treatment was 28 d for both groups.The activities of daily living(ADL)score,National Institutes of Health Stroke Scale(NIHSS)score,quality of life score,TCM syndrome score,and safety in both groups were observed before treatment and at 14 and 28 d post treatment,and their clinical outcome was evaluated.[Results]There was a significant difference in overall response rate between the treatment group and the control group[92.00%(23/25)vs 76.00%(19/25),P<0.05].After treatment,both groups had significant changes in ADL score,NIHSS score,quality of life score,and TCM syndrome score,and there were significant differences in these indices between the two groups at the same time point after treatment(P<0.05 or P<0.01).There were no significant changes in routine blood,routine stool,routine urine,and liver/renal function in either group after treatment.[Conclusions]Fuyang prescription has a marked clinical effect in the treatment of yang deficiency syndrome in the convalescent stage of IS,with significantly better clinical effect than Buyang Huanwu decoction,and it provides clinical evidence for the traditional Chinese medicine theory of yang supporting in the treatment of IS in the convalescent stage.展开更多
基金Supported by National Natural Science Foundation of China(81874453)Natural Science Foundation of Guangxi Zhuang Autonomous Region(2020JJB140540)+5 种基金Innovation Team of Clinical Medicine Research and Application of Zhuang Medical Toxicities(04B22058A3)Guangxi Clinical Research Center for Encephalopathy of Traditional Chinese Medicine(AD20238028)The Second Batch of"Qihuang Project"High-level Talent Team Cultivation Project of Guangxi University of Traditional Chinese Medicine(2021008)Chinese Medicine Self-financing Project of Traditional Chinese Medicine Administration of Guangxi Zhuang Autonomous Region(GXZYZ20210350)Graduate Education Innovation Program of Guangxi University of Traditional Chinese Medicine(YCBZ2021076)Hospital-level Project of Guangxi International Zhuang Medical Hospital(GZ2021007)。
文摘[Objectives]The paper was to investigate the clinical effect of Fuyang prescription in the treatment of yang deficiency syndrome in the convalescent stage of ischemic stroke(IS)and its mechanism of action.[Methods]A total of 50 patients with yang deficiency syndrome in the convalescent stage of IS were randomly divided into treatment group and control group,with 25 patients in each group.The patients in the treatment group were given basic treatment combined with Fuyang prescription,and those in the control group were given basic treatment combined with Buyang Huanwu decoction;the course of treatment was 28 d for both groups.The activities of daily living(ADL)score,National Institutes of Health Stroke Scale(NIHSS)score,quality of life score,TCM syndrome score,and safety in both groups were observed before treatment and at 14 and 28 d post treatment,and their clinical outcome was evaluated.[Results]There was a significant difference in overall response rate between the treatment group and the control group[92.00%(23/25)vs 76.00%(19/25),P<0.05].After treatment,both groups had significant changes in ADL score,NIHSS score,quality of life score,and TCM syndrome score,and there were significant differences in these indices between the two groups at the same time point after treatment(P<0.05 or P<0.01).There were no significant changes in routine blood,routine stool,routine urine,and liver/renal function in either group after treatment.[Conclusions]Fuyang prescription has a marked clinical effect in the treatment of yang deficiency syndrome in the convalescent stage of IS,with significantly better clinical effect than Buyang Huanwu decoction,and it provides clinical evidence for the traditional Chinese medicine theory of yang supporting in the treatment of IS in the convalescent stage.
